Business

Horizon Pharma has agreed to sell Raptor Pharmaceuticals, which owns the rights to Quinsair levofloxacin inhalation solution in Europe, the Middle East and Africa, to Chiesi Farmaceutici for $70 million and potential sales-based milestone payments, the company said. Horizon will retain rights to Quinsair and another product, Procysbi, in the US, Canada, and Latin … [Read more...] about Chiesi to acquire Raptor Pharmaceuticals and its rights to Quinsair levofloxacin inhalation solution in EMEA regions

Windtree Therapeutics has received $900,000 from a Small Business Innovation Research Grant (SBIR) grant for Phase 2b trial of Aerosurf aerosolized KL4 surfactant in premature infants with respiratory distress syndrome (RDS) who are receiving nasal continuous positive airway pressure (nCPAP), the company said. In August 2016, Windtree announced that it had … [Read more...] about Windtree Therapeutics gets $900,000 from SBIR grant

Pharmaxis has announced that Chiesi Farmaceutici will take over marketing and distribution of Bronchitol mannitol DPI in Italy. Bronchitol has been approved in the EU for the treatment of cystic fibrosis in patients 18 years old and older since 2012. In 2015, Pharmaxis and Chiesi announced an agreement for distribution rights to Bronchitol in the UK, Ireland, and … [Read more...] about Chiesi to distribute Pharmaxis’s Bronchitol mannitol DPI in Italy

Pulmatrix has announced the receipt of US patent No. 9,642,798, titled "Monovalent metal cation dry powders for inhalation," which covers its PUR0200 dry powder formulation of tiotropium bromide for the treatment of COPD. In July 2016, Pulmatrix announced positive Phase 1 results for PUR0200. The company has previously received a number of patents for its iSPERSE … [Read more...] about Pulmatrix gets US patent covering PUR0200 tiotropium bromide formulation

According to intranasal drug developer OptiNose, the company has raised $37 million in a Series D financing round led by Fidelity Management and Research Company. The company said that it plans to use the money to prepare for the US launch of OPN-375 intranasal fluticasone propionate if approved. OptiNose submitted an NDA for OPN-375 for the treatment of nasal … [Read more...] about OptiNose raises $37 million to prepare for launch of OPN-375

Innovus Pharmaceuticals will launch a fluticasone propionate nasal spray under the brand name FlutiCare in the US by the end of 2017 after acquiring rights to the product from West-Ward Pharmaceuticals International Limited (WWPIL). The 50μg per spray FlutiCare is equivalent to GSK's Flonase, and the company said that it expects revenue from sales of the product in … [Read more...] about Innovus Pharmaceuticals acquires US rights to fluticasone propionate nasal spray from West-Ward

The US Patent and Trademark Office has issued US Patent No. 9,572,774, titled "Dry Powder Vancomycin Compositions and Associated Methods," to inhaled drug developer Savara, Inc., the company said. In its statement, the company added, "This affords Savara important composition of matter protection for its AeroVanc program in the US, the largest market for the … [Read more...] about Savara receives US and Canadian patents for AeroVanc

AstraZeneca will pay $45 million up front and up to $2.1 billion in milestone and commercial payments to Pieris Pharmaceuticals for development and commercialization rights to Pieris's inhaled anticalin therapies, Pieris said. In the near term, AstraZeneca will also provide $12.5 million for a Phase 1 trial of Pieris's lead candidate PRS-060, which is expected to … [Read more...] about AstraZeneca to collaborate with Pieris on inhaled anticalins for the treatment of respiratory disease

The US National Institutes of Health (NIH) has published two funding opportunity announcements (FOAs) related to nasal delivery of CNS therapeutics. The projects described in FOAs RFA-DA-18-006 and RFA-DA-18-007 are both supported by Small Business Technology Transfer (STTR) program Both FOAs say that their purpose is to "is to develop a nasal delivery formulation … [Read more...] about NIH announces funding opportunity for nasal delivery of CNS therapeutics